Bayer Acquires Attralus Radiotracers, Expands into Molecular Imaging

Bayer is acquiring two investigational molecular imaging agents from Attralus for the diagnosis of cardiac amyloidosis. AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) are two tracers currently in clinical development. Potentially, they may address the urgent need to accurately diagnose a disease that affects approximately 400,000 people globally.

“With this strategic acquisition and the integration of novel molecular tracers into our development portfolio, we are advancing Bayer’s innovation strategy,” said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division. “AT-01 and AT-05 are precisely engineered to detect cardiac amyloidosis with high accuracy, enabling timely intervention and improved patient outcomes.”

Bayer’s Foray into Imaging

“With new therapies emerging for often insufficiently treated conditions such as cardiac amyloidosis, it becomes increasingly relevant to precisely detect and monitor diseases on the molecular level,” said Nelson Ambrogio, President, Radiology at Bayer. “We will further advance scientific progress with the aim to broaden diagnostic options and make a meaningful difference for people.”

“Despite recent progress in systemic amyloidosis, most patients continue to remain undiagnosed,” said Glen Firestone, President of Attralus. “Consistent with Attralus’ mission, we believe that these pan-amyloid imaging agents will enable earlier diagnosis and treatment, leading to improved patient outcomes.”

Tracers a Lucrative and Growing Market

Though Bayer and Attralus did not disclose specific financial terms for the agreement, the global market for radio-diagnostic tracers is expanding. Its value, approximately $3 billion in 2024, expects to appreciate significantly in the years ahead.

Bayer said clinical recognition of cardiac amyloidosis at an early stage is important for adequate, effective patient management given the therapeutic options that currently exist.